PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21565247-0	2011	Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: the potential involvement of p21 expression and p53 phosphorylation.	Arsenic Trioxide	0-16	transformation related protein 53, pseudogene	Mus musculus	105-108	
33357454-6	2021	In cellular and mouse xenograft models, ATO reactivates mutant p53 for tumor suppression.	Arsenic Trioxide	40-43	transformation related protein 53, pseudogene	Mus musculus	63-66	
20624968-4	2010	Arsenicals active in Hh pathway antagonism include arsenic trioxide (ATO), a curative agent in clinical use for acute promyelocytic leukemia (APL); in our studies, ATO inhibited growth of Hh pathway-driven medulloblastoma allografts derived from Ptch+/-p53-/- mice within a range of serum levels comparable to those achieved in treatment of human APL.	Arsenic Trioxide	51-67	transformation related protein 53, pseudogene	Mus musculus	253-256	
20624968-4	2010	Arsenicals active in Hh pathway antagonism include arsenic trioxide (ATO), a curative agent in clinical use for acute promyelocytic leukemia (APL); in our studies, ATO inhibited growth of Hh pathway-driven medulloblastoma allografts derived from Ptch+/-p53-/- mice within a range of serum levels comparable to those achieved in treatment of human APL.	Arsenic Trioxide	69-72	transformation related protein 53, pseudogene	Mus musculus	253-256	
20624968-4	2010	Arsenicals active in Hh pathway antagonism include arsenic trioxide (ATO), a curative agent in clinical use for acute promyelocytic leukemia (APL); in our studies, ATO inhibited growth of Hh pathway-driven medulloblastoma allografts derived from Ptch+/-p53-/- mice within a range of serum levels comparable to those achieved in treatment of human APL.	Arsenic Trioxide	164-167	transformation related protein 53, pseudogene	Mus musculus	253-256